Anna D. Garrett, PharmD, BCPS, CPP
Published Online: Saturday, September 1, 2007

Studies of 2 new oral anticoagulants, rivaroxaban and dabigatran, in joint replacement patients have yielded positive results for prevention of venous thromboembolism (VTE). Results of the studies were recently presented at the 2007 Congress of the International Society on Thrombosis and Hemostasis. Results obtained with rivaroxaban suggested superior efficacy and similar bleeding rates when compared with enoxaparin. Two studies were presented for dabigatran, the results of which were conflicting. In the RE-NOVATE trial, dabigatran showed equivalence to 40 mg of enoxaparin, while in the RE-MOBILIZE study it failed to show equivalence to a 60-mg dose of enoxaparin.

The 2 new oral anticoagulants are among a number of compounds under development that may one day replace warfarin. Neither of the drugs needs regular monitoring. Liver-toxicity problems, which caused a predecessor drug (ximelagatran) to be rejected by the FDA, have not been noted. Dabigatran appears closest to market, having already been filed for approval in Europe. Approval applications for prevention of VTE are expected to be filed for rivaroxaban in the United States in 2008. Both drugs are also under study for use in atrial fibrillation and acute coronary syndromes.

Latest Articles
This weekly video program highlights the latest in pharmacy news, product news, and more.
Propranolol is red, digoxin is blue. Your pharmacist’s heart may skip a beat if they get a valentine from you.
Health-system pharmacists can play a critical role in managing drug shortages to prevent medical errors and adverse events.
The White House is asking Congress for more than $1.8 billion in emergency funding to combat the Zika virus, which is creeping into the United States and ravaging some foreign countries.
Latest Issues